ECM
CORT icon

Element Capital Management’s Corcept Therapeutics CORT Stock Holding History

Element Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-28,002
Closed -$329K – 356
2019
Q1 		$329K Buy
+28,002
New +$348K 0.01% 562

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Element Capital Management's CORT Position: Q2 2019 in Review

Element Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 28,002 shares — an estimated $329K sold.

Element Capital Management first reported a position in CORT in Q1 2019 and held it in 1 quarter. The position peaked at $329K in Q1 2019. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Element Capital Management reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Element Capital Management sold 28,002 Corcept Therapeutics shares in Q2 2019, an estimated $329K.
  • Element Capital Management first reported a position in Corcept Therapeutics in Q1 2019 and held it in 1 quarter.
  • Element Capital Management's Corcept Therapeutics position peaked at $329K in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.